MARKER THERAPEUTICS, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
MARKER THERAPEUTICS, INC. (MRKR) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$10.73 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2025-03-31
- MARKER THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-12-31 was -$3.84M.
- MARKER THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-09-30 was -$2.31M.
- MARKER THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-06-30 was -$2.19M.
- MARKER THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-03-31 was -$2.39M.
- MARKER THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$10.73M.
- MARKER THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$14.05M.
- MARKER THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$19.78M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$3.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$6.15M derived: sum of 2 quarters · filed 2025-03-31 | -$8.34M derived: sum of 3 quarters · filed 2025-03-31 | -$10.73M 10-K · filed 2025-03-31 |
| 2024-09-30 | -$2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$4.50M derived: sum of 2 quarters · filed 2024-11-14 | -$6.89M 10-Q · filed 2024-11-14 | -$9.63M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | -$2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$4.59M 10-Q · filed 2024-08-14 | -$7.33M derived: sum of 3 quarters · filed 2025-03-31 | -$10.31M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | -$2.39M 10-Q · filed 2024-05-15 | -$5.13M derived: sum of 2 quarters · filed 2025-03-31 | -$8.11M derived: sum of 3 quarters · filed 2025-03-31 | -$12.21M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | -$2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$5.72M derived: sum of 2 quarters · filed 2025-03-31 | -$9.82M derived: sum of 3 quarters · filed 2025-03-31 | -$14.05M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$2.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$7.08M derived: sum of 2 quarters · filed 2024-11-14 | -$11.31M 10-Q · filed 2024-11-14 | -$14.35M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$4.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$8.32M 10-Q · filed 2024-08-14 | -$11.37M derived: sum of 3 quarters · filed 2024-08-14 | -$17.09M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$4.22M 10-Q · filed 2024-05-15 | -$7.27M derived: sum of 2 quarters · filed 2024-05-15 | -$12.99M derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$8.77M derived: sum of 2 quarters · filed 2024-03-26 | -$19.78M 10-K · filed 2024-03-26 | |
| 2022-09-30 | -$5.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$16.73M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$11.01M 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |